As clinical and experimental evidence suggests that administering PPARγ agonists are protective against hypertension [28,29], our data implied that maternal melatonin therapy inducing Pparg to regulate its target genes might be a beneficial mechanism, at least in part, by which melatonin reprograms hypertension of developmental origin. This evidence concerns the gene PPARG and hypertensive disorder.